PCM
NERV icon

Poehling Capital Management’s Minerva Neurosciences NERV Stock Holding History

Poehling Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25
Closed -$1K – 327
2017
Q4 		$1K Buy
+25
New +$1.24K ﹤0.01% 273

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAV
Index Venture Associates V St. Helier, Channel Islands, Jersey $1.46M AUM 88.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Poehling Capital Management's NERV Position: Q1 2018 in Review

Poehling Capital Management sold out of Minerva Neurosciences (NERV) in Q1 2018, closing a stake of 25 shares — an estimated $1K sold.

Poehling Capital Management first reported a position in NERV in Q4 2017 and held it in 1 quarter. The position peaked at $1K in Q4 2017. 67 funds tracked by Wall St. Rank hold NERV as of Q1 2018.

  • Poehling Capital Management reported no remaining Minerva Neurosciences position as of Q1 2018 after selling out during the quarter.
  • Poehling Capital Management sold 25 Minerva Neurosciences shares in Q1 2018, an estimated $1K.
  • Poehling Capital Management first reported a position in Minerva Neurosciences in Q4 2017 and held it in 1 quarter.
  • Poehling Capital Management's Minerva Neurosciences position peaked at $1K in Q4 2017.
  • 67 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2018.

Based on Poehling Capital Management's 13F filing for Q1 2018, filed 14 May 2018.